{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:37:14Z","timestamp":1792521434445,"version":"4.5.0"},"reference-count":24,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,2,1]]},"abstract":"<jats:p>BACKGROUND. In the United States, children receive primary doses of M-M-RII (Merck &amp; Co, Inc, West Point, PA) and Varivax (Merck &amp; Co, Inc) beginning at 12 months, often at the same health care visit. Currently a second dose of M-M-RII is given to 4- to 6-year-old children, to increase vaccination rates and to reduce the number of individuals without detectable antibodies. A second dose of a varicella-containing vaccine may result in similar benefits.<\/jats:p>\n                  <jats:p>OBJECTIVES. To demonstrate that ProQuad (measles, mumps, rubella, and varicella virus vaccine live; Merck &amp; Co, Inc) may be given in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.<\/jats:p>\n                  <jats:p>METHODS. Four- to 6-year-old children who had been immunized previously with M-M-RII and Varivax were assigned randomly to receive either ProQuad and placebo (N = 399), M-M-RII and placebo (N = 195), or M-M-RII and Varivax (N = 205) and were then monitored for safety and immunogenicity.<\/jats:p>\n                  <jats:p>RESULTS. ProQuad was generally well tolerated. Similarity (noninferiority) was demonstrated in postvaccination antibody responses to measles, mumps, and rubella between recipients of ProQuad and all recipients of M-M-RII and in responses to varicella between recipients of ProQuad and recipients of Varivax. Postvaccination seropositivity rates for antibodies against all 4 viruses were nearly 100% in all 3 groups. Small fold increases were observed for measles, mumps, and rubella antibody titers. In contrast, substantial boosts in varicella antibody titers were observed among recipients of a second dose of varicella vaccine, administered as ProQuad or Varivax.<\/jats:p>\n                  <jats:p>CONCLUSIONS. ProQuad may be used in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.<\/jats:p>","DOI":"10.1542\/peds.2005-0092","type":"journal-article","created":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T14:21:17Z","timestamp":1138803677000},"page":"265-272","source":"Crossref","is-referenced-by-count":43,"title":["A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax"],"prefix":"10.1542","volume":"117","author":[{"given":"Keith S.","family":"Reisinger","sequence":"first","affiliation":[{"name":"Primary Physicians Research, Pittsburgh, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Hoffman Brown","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Marshfield Clinic, Marshfield, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Marshall","sequence":"additional","affiliation":[{"name":"Division of Pediatric Infectious Diseases, University of Louisville School of Medicine, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Nauert","sequence":"additional","affiliation":[{"name":"Radiant Research, Austin, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Matson","sequence":"additional","affiliation":[{"name":"Center for Pediatric Research, Eastern Virginia Medical School, Norfolk, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Silas","sequence":"additional","affiliation":[{"name":"Wee Care Pediatrics, Layton, Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Protocol 014 Study Group for ProQuad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Scho\u0308del","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline O.","family":"Gress","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"Merck Research Laboratories, West Point, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2006,2,1]]},"reference":[{"key":"2021120820073126500_R1","unstructured":"Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, July\u2013December 2004. MMWR Morb Mortal Wkly Rep.\u20082004;53(16):Q1\u2013Q3"},{"key":"2021120820073126500_R2","unstructured":"Shinefield H, Black S, Eves K, et al. Tolerability and immunogenicity of one and two dose regimen of ProQuad in healthy children. Presented at the 41st annual meeting of the Infectious Disease Society of America; October 9\u201312,2003; San Diego, CA"},{"key":"2021120820073126500_R3","doi-asserted-by":"crossref","unstructured":"Kuter B, Matthews H, Shinefield H, et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J.\u20082004;23:132\u2013137","DOI":"10.1097\/01.inf.0000109287.97518.67"},{"key":"2021120820073126500_R4","doi-asserted-by":"crossref","unstructured":"Li S, Chan I, Matthews H, et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J.\u20082002;21:337\u2013342","DOI":"10.1097\/00006454-200204000-00014"},{"key":"2021120820073126500_R5","doi-asserted-by":"crossref","unstructured":"Keller PM, Lonergan K, Neff BJ, et al. Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies. J Virol Methods.\u20081986;14:177\u2013188","DOI":"10.1016\/0166-0934(86)90048-0"},{"key":"2021120820073126500_R6","doi-asserted-by":"crossref","unstructured":"Wasmuth EH, Miller WJ. Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen. J Med Virol.\u20081990;32:189\u2013193","DOI":"10.1002\/jmv.1890320310"},{"key":"2021120820073126500_R7","doi-asserted-by":"crossref","unstructured":"Provost PJ, Krah DL, Kuter BJ, et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine.\u20081991;9:111\u2013116","DOI":"10.1016\/0264-410X(91)90266-9"},{"key":"2021120820073126500_R8","doi-asserted-by":"crossref","unstructured":"White CJ, Kuter BJ, Ngai A, et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr Infect Dis J.\u20081992;11:19\u201323","DOI":"10.1097\/00006454-199201000-00006"},{"key":"2021120820073126500_R9","doi-asserted-by":"crossref","unstructured":"Hilleman MR, Weibel RE, Buynak EB, et al. Live, attenuated mumps-virus vaccine, 4: protective efficacy as measured in a field evaluation. N Engl J Med.\u20081967;276:252\u2013258","DOI":"10.1056\/NEJM196702022760502"},{"key":"2021120820073126500_R10","unstructured":"Centers for Disease Control and Prevention. Decline in annual incidence of varicella: selected states, 1990\u20132001. MMWR Morb Mortal Wkly Rep.\u20082003;52:884\u2013885"},{"key":"2021120820073126500_R11","doi-asserted-by":"crossref","unstructured":"Nguyen HQ, Jumaan AO, Seward JF. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med.\u20082005;352:450\u2013458","DOI":"10.1056\/NEJMoa042271"},{"key":"2021120820073126500_R12","unstructured":"Centers for Disease Control and Prevention. Varicella-related deaths: United States, January 2003\u2013June 2004. MMWR Morb Mortal Wkly Rep.\u20082005;54:272\u2013274"},{"key":"2021120820073126500_R13","doi-asserted-by":"crossref","unstructured":"Seward JF, Watson BM, Peterson CL, et al. Varicella disease after introduction of varicella vaccine in the United States, 1995\u20132000. JAMA.\u20082002;287:606\u2013611","DOI":"10.1001\/jama.287.5.606"},{"key":"2021120820073126500_R14","unstructured":"Maupin T, Civen R, Jumaan A, et al. Varicella outbreaks in an active surveillance site: Antelope Valley, CA, 1995\u20132003. Presented at the 38th Annual National Immunization Conference; May 11\u201314,2004; Nashville, TN"},{"key":"2021120820073126500_R15","doi-asserted-by":"crossref","unstructured":"Vazquez M, LaRussa PS, Gershon AA, et al. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med.\u20082001;344:955\u2013960","DOI":"10.1056\/NEJM200103293441302"},{"key":"2021120820073126500_R16","doi-asserted-by":"crossref","unstructured":"Clements DA, Moreira SP, Coplan PM, et al. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J.\u20081999;18:1047\u20131050","DOI":"10.1097\/00006454-199912000-00004"},{"key":"2021120820073126500_R17","doi-asserted-by":"crossref","unstructured":"Galil K, Fair E, Mountcastle N, Britz P, Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis.\u20082002;186:102\u2013105","DOI":"10.1086\/341089"},{"key":"2021120820073126500_R18","unstructured":"Merck & Co, Inc. USA package circular: Varivax (varicella virus [Oka\/Merck & Co, Inc] vaccine live). West Point, PA: Merck & Co, Inc;2003"},{"key":"2021120820073126500_R19","unstructured":"Centers for Disease Control and Prevention. National, state, and urban vaccination coverage among children aged 19\u201335 months: United States, 2003. MMWR Morb Mortal Wkly Rep.\u20082004;53:658\u2013661"},{"key":"2021120820073126500_R20","doi-asserted-by":"crossref","unstructured":"Ngai A, Staehle B, Kuter B, et al. Safety and immunogenicity of one vs. two injections of Oka\/Merck varicella vaccine in healthy children. Pediatr Infect Dis J.\u20081996;15:49\u201354","DOI":"10.1097\/00006454-199601000-00011"},{"key":"2021120820073126500_R21","doi-asserted-by":"crossref","unstructured":"Watson B, Rothstein E, Bernstein H, et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis.\u20081995;172:217\u2013219","DOI":"10.1093\/infdis\/172.1.217"},{"key":"2021120820073126500_R22","unstructured":"Shinefield H, Black S, Marchant C, et al. A dose selection study in healthy children comparing measles, mumps, rubella, and varicella (ProQuad) vaccine to M-M-RII given concomitantly with process upgrade varicella vaccine (PUVV) in separate injections. Presented at the 20th Annual Meeting of the European Society for Paediatric Infectious Diseases; May 29\u201331,2002; Vilnius, Lithuania"},{"key":"2021120820073126500_R23","doi-asserted-by":"crossref","unstructured":"Tugwell BD, Lee LE, Gillette H, et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics.\u20082004;113:455\u2013459","DOI":"10.1542\/peds.113.3.455"},{"key":"2021120820073126500_R24","unstructured":"Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep.\u20081999;48(RR-5):1\u201315"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/2\/265\/1012347\/zpe00206000265.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/117\/2\/265\/1012347\/zpe00206000265.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T18:39:13Z","timestamp":1638988753000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/117\/2\/265\/68490\/A-Combination-Measles-Mumps-Rubella-and-Varicella"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2,1]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,2,1]]},"published-print":{"date-parts":[[2006,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-0092","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,2,1]]}}}